|Title:||Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology||Authors:||Recio Cruz, Carlota Pilar
Guerra Rodríguez, Miguel Alfonso
Aranda Tavío, Haidee Magdalena
de Mirecki-Garrido, Mercedes
García-Castellano, José M.
Fernández Pérez, Leandro Fco
|UNESCO Clasification:||320101 Oncología
Self-Renewal, et al
|Issue Date:||2019||Project:||Desarrollo Preclínico de Nuevas Estructuras Bioactivas Moduladoras de Las Actividades Oncogénicas de Stat3/5 O de Los Receptores de Estrógenos||Journal:||Oncogene||Abstract:||The signal transducer and activator of transcription (STAT) are transcription factors that work via JAK/STAT pathway regulating the expression of genes involved in cell survival, proliferation, differentiation, development, immune response, and, among other essential biological functions, hematopoiesis. JAK/STAT signaling is strictly regulated under normal physiological conditions. However, a large group of diverse diseases has been associated to an aberrant regulation of STAT factors. Erroneous modulation of the pathway leads to constitutive STAT activation, thereby driving proliferation, inflammation, and an uncontrolled immune response. Deregulated STAT5 activation has been found in the development of many hematopoietic tumors, including chronic and acute leukemias, polycythemia vera, and lymphoma. Mutations in the kinases that phosphorylate STAT5, and/or overexpression of the upstream receptor-associated tyrosine kinases have been suggested as the main drivers of constitutive STAT5 activation. Hyper-activated STAT5 leads to the aberrant expression of its target genes including antiapoptotic, proliferative, and pro-inflammatory genes, favouring tumorigenesis. In this review, we intent to discuss the biology of JAK/STAT pathway, with particular focus on STAT5 and its crucial role in the development and progression of hematologic malignancies. Furthermore, we provide a synopsis of potential therapeutic strategies based on STAT5 activity inhibition that may represent an excellent opportunity for drug development in oncohematology.||URI:||http://hdl.handle.net/10553/69816||ISSN:||0950-9232||DOI:||10.1038/s41388-019-0752-3||Source:||Oncogene [ISSN 0950-9232], v. 38 (24), p. 4657-4668|
|Appears in Collections:||Artículos|
checked on May 9, 2021
WEB OF SCIENCETM
checked on May 9, 2021
checked on May 10, 2021
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.